Brief: Abbisko Cayman Enters Exclusive Out-License Agreement With Shanghai Allist Pharmaceuticals
01/03/2023 13:56
March 1 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* ENTERED EXCLUSIVE OUT-LICENSE AGREEMENT WITH SHANGHAI
ALLIST
PHARMACEUTICALS CO., LTD.
* AGREEMENT FOR RESEARCH, DEVELOPMENT, MANUFACTURE, USE, AND
SALES
OF (EGFR-TKI) ABK3376 IN CHINA
Further company coverage: 2256.HK
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly